Sat Kartar Life Ltd
Sat Kartar Life Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
What the Q4 FY26 call signalled
4 of 4 strong
The short version
FY 27 product revenue target: ₹300 crores, driven by: - Current run rate at ₹225 crores with expected 25% growth in current business. FY26 PAT margin grew from 6% to 8.5% with revenue growth from 160 to 200 crore.
From Sat Kartar Life Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY 27 product revenue target: ₹300 crores, driven by:
- Current run rate at ₹225 crores with expected 25% growth in current business.
- Subsidiaries contributing ~₹22 crores.
- US operations adding ₹10-15 crores.
- AI efficiencies and nutraceuticals (Ajooni Life Sciences) adding ~₹20 crores.
- FY 28 product revenue target: ₹500 crores, fueled by:
- New high-ticket products.
- Better product margins.
- Controlled advertisement spend.
- Increased ticket size and scaling sales.
- Hospital business expansion:
- 300 beds target by end FY 27, starting simultaneous set-up of 4 facilities.
- Plan to expand to 1000 beds by FY 28.
- Hospital margins expected at 30-35% at 60% occupancy.
2 more points from Sat Kartar Life Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
Read what Sat Kartar Life Ltd said on margins in the Q4 FY26 call
Free account with your mobile number. We text a one-time code, no password.
Capital Expenditure Plans
- Current capex includes upgrading existing manufacturing facility (capsule and powder units) with an investment of around ₹1-1.25 crore.
- Hospital bed setup capex is estimated at ₹7-8 lakhs per bed, with ₹4 lakhs considered as fixed asset cost and the balance as working capital.
- For the planned 1000 beds, estimated capex is around ₹40 crore (₹4 lakh per bed).
- Capital for initial phases of hospital expansion raised with ₹45 crore in the bank to build the first phase.
- Subsequent phases to be funded through internal cash generation and possibly debt; no current plans for further equity dilution.
2 more points from Sat Kartar Life Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sat Kartar Life Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- As per the transcript on page 7, the number of orders can be estimated by dividing revenue by ticket size: FY26 revenue was ₹200 crores and ticket size around ₹3,250, implying approximately 6.15 million orders.
- Current business run rate is around ₹225 crores, expecting growth to ₹300 crores in FY27 with new initiatives contributing additional ₹50-₹55 crores.
- Growth drivers include subsidiaries, US operations, AI improvements, nutraceuticals via Ajooni Life Sciences, and geographic expansion in under-penetrated markets.
2 more points from Sat Kartar Life Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Sat Kartar Life Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
Arthneeti Pro · Annual
Sat Kartar Life Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sat Kartar Life Ltd Q4 FY26 results?
FY 27 product revenue target: ₹300 crores, driven by: - Current run rate at ₹225 crores with expected 25% growth in current business. FY26 PAT margin grew from 6% to 8.5% with revenue growth from 160 to 200 crore.
What is Sat Kartar Life Ltd share price analysis?
Sat Kartar Life Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 11.4 with a market cap of ₹196 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sat Kartar Life Ltd planning capital expenditure?
Current capex includes upgrading existing manufacturing facility (capsule and powder units) with an investment of around ₹1-1.25 crore.
Keep Sat Kartar Life Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.